A review, chaired by Sir Michael Rawlins, is set to announce proposals to speed up approval for clinical research using human embryos. This follows criticism from scientists and drug companies alike, who believe that there is too much red tape surrounding the current regulations. However, this may adversely impact upon the protection afforded to human embryos by Human Fertilisation and Embryology Act 1990, sch. 2 para 3A. The proposals have been criticised by the Human Fertilisation & Embryology Authority who are concerned that a more clinically driven regulatory authority would not be appropriate.